Given that PLK1 inhibitors exhibit strong antiproliferative activity in NSCLC cells and have clinical relevance in EGFR-mutated patients, we further evaluated the efficacy of their combination with EGFR-TKIs to enhance therapeutic effects and reduce potential toxic side effects. The gene discussed is PLK1; the disease is non-small cell lung carcinoma.